Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107)

INTRODUCTION: The Cancer and Leukemia Group B (CALGB) conducted a multi-center phase II trial to evaluate the efficacy and safety of vatalanib in previously untreated patients with malignant mesothelioma and to evaluate potential biomarkers of disease response (CALGB 30107). METHODS: Treatment consi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Lung Cancer
Autori principali: Jahan, Thierry, Gu, Lin, Kratzke, Robert, Dudek, Arkadiusz, Otterson, Gregory A., Wang, Xiaofei, Green, Mark, Vokes, Everett E., Lee Kindler, Hedy
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2011
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4778731/
https://ncbi.nlm.nih.gov/pubmed/22197613
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2011.11.014
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi